A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Ultragenyx Pharmaceutical Inc.
RARE
$2.7B
Mkt Cap
$26.90
-0.44%
Ultragenyx Pharmaceutical Inc. (RARE) has a 5-year average return on invested capital (ROIC) of -89.0%. This is below average and may indicate limited pricing power.
Ultragenyx Pharmaceutical Inc. (RARE) has a market capitalization of $2.7B. It is classified as a mid-cap stock.
Ultragenyx Pharmaceutical Inc. (RARE) does not currently pay a regular dividend.
Ultragenyx Pharmaceutical Inc. (RARE) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Ultragenyx Pharmaceutical Inc. (RARE) reported annual revenue of $673 million in its most recent fiscal year, based on SEC EDGAR filings.
Ultragenyx Pharmaceutical Inc. (RARE) has a net profit margin of -85.4%. The company is currently unprofitable.
Ultragenyx Pharmaceutical Inc. (RARE) generated $-472 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
We are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. We have built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. We were founded in April 2010 by our President and Chief Executive Officer, Emil Kakkis, M.D., Ph.D., and are led by a management team experienced in the development and commercialization of rare disease therapeutics. Our strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. Our Strategy The critical components of our business strategy include the following: •Focus on rare and ultra-rare genetic diseases with significant unmet medical need and clear biology.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 673M | 673M | 560M | 434M | 363M | 351M |
| Net Income | -575M | -575M | -569M | -607M | -707M | -454M |
| EPS | $-5.83 | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 |
| Free Cash Flow | -472M | -472M | -421M | -519M | -497M | -412M |
| ROIC | -27.6% | -34.9% | -166.1% | -163.3% | -33.2% | -47.6% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -20.15 | 4.87 | 4.41 | 0.09 | 0.05 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -535M | -535M | -536M | -569M | -649M | -382M |
| Operating Margin | -79.5% | -79.5% | -95.7% | -131.1% | -178.6% | -108.6% |
| ROE | 0.0% | -657.1% | -223.1% | -220.3% | -200.7% | -49.2% |
| Shares Outstanding | 99M | 99M | 90M | 74M | 70M | 68M |
| Metric | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | N/A | N/A | N/A | N/A | 271M | 351M | 363M | 434M | 560M | 673M | 673M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 183M | 232M | 294M | 357M | 412M | 497M | 706M | 648M | 698M | 750M | 750M |
| SG&A | 65M | 100M | 128M | 162M | 183M | 220M | 278M | 310M | 321M | 349M | 349M |
| EBIT | -248M | -329M | -371M | -424M | -330M | -382M | -649M | -569M | -536M | -535M | -535M |
| Op. Margin | N/A | N/A | N/A | N/A | -121.8% | -108.6% | -178.6% | -131.1% | -95.7% | -79.5% | -79.5% |
| Net Income | -246M | -302M | -198M | -403M | -187M | -454M | -707M | -607M | -569M | -575M | -575M |
| Net Margin | N/A | N/A | N/A | N/A | -68.8% | -129.2% | -194.7% | -139.7% | -101.6% | -85.4% | -85.4% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||
| ROIC | -51.9% | -78.8% | -32.5% | -58.9% | -15.6% | -47.6% | -33.2% | -163.3% | -166.1% | -34.9% | -27.6% |
| ROE | -51.9% | -78.8% | -32.5% | -61.6% | -16.2% | -49.2% | -200.7% | -220.3% | -223.1% | -657.1% | 0.0% |
| ROA | -45.5% | -61.6% | -27.5% | -35.5% | -10.6% | -29.8% | -45.8% | -40.7% | -37.9% | -37.9% | -37.5% |
| Cash Flow | |||||||||||
| Op. Cash Flow | -161M | -254M | -291M | -345M | -132M | -339M | -380M | -475M | -414M | -466M | -466M |
| Free Cash Flow | -171M | -257M | -295M | -370M | -176M | -412M | -497M | -519M | -421M | -472M | -472M |
| Owner Earnings | -213M | -328M | -390M | -436M | -230M | -457M | -529M | -636M | -608M | -654M | -654M |
| CapEx | 10M | 2.8M | 4.1M | 25M | 44M | 73M | 116M | 44M | 7.0M | 6.0M | 6.0M |
| Maint. CapEx | 3.4M | 5.8M | 20M | 8.5M | 12M | 13M | 18M | 26M | 36M | 35M | 35M |
| Growth CapEx | 6.8M | 0 | 0 | 16M | 32M | 60M | 98M | 18M | 0 | 0 | 0 |
| D&A | 3.4M | 5.8M | 20M | 8.5M | 12M | 13M | 18M | 26M | 36M | 35M | 35M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 48M | 68M | 80M | 82M | 86M | 105M | 130M | 135M | 158M | 153M | 153M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||
| Net Debt | N/A | N/A | N/A | -718M | -1.2B | -698M | -716M | N/A | N/A | N/A | -421M |
| Cash & Equiv. | 161M | 100M | 113M | 434M | 714M | 308M | 133M | 214M | 174M | 421M | 421M |
| Long-Term Debt | N/A | N/A | N/A | 30M | 39M | 31M | 20M | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.14 | 0.28 | 0.18 | 0.06 | 0.04 | 0.05 | 0.09 | 4.41 | 4.87 | -20.15 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | -373.7 | -9.9 | -13.0 | -15.1 | -8.6 | -8.5 | -8.6 | -8.6 |
| Equity | 474M | 383M | 609M | 654M | 1.2B | 923M | 352M | 275M | 255M | -80M | -80M |
| Total Assets | 541M | 491M | 720M | 1.1B | 1.8B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Total Liabilities | 67M | 107M | 111M | 482M | 605M | 600M | 1.2B | 1.2B | 1.2B | 1.6B | 1.6B |
| Intangibles | N/A | 186M | 174M | 173M | 176M | 175M | 205M | 211M | 222M | 220M | 220M |
| Retained Earnings | -531M | -833M | -1.0B | -1.4B | -1.6B | -2.1B | -2.8B | -3.4B | -4.0B | -4.5B | -4.5B |
| Working Capital | 341M | 199M | 448M | 748M | 1.1B | 675M | 623M | 452M | 473M | 567M | 567M |
| Current Assets | 402M | 270M | 522M | 851M | 1.3B | 857M | 884M | 732M | 817M | 951M | 951M |
| Current Liabilities | 60M | 71M | 75M | 103M | 190M | 181M | 261M | 280M | 344M | 384M | 384M |
| Per Share Data | |||||||||||
| EPS | -6.21 | -7.12 | -3.97 | -7.12 | -3.07 | -6.70 | -10.12 | -8.25 | -6.29 | -5.83 | -5.83 |
| Owner EPS | -5.37 | -7.72 | -7.84 | -7.71 | -3.79 | -6.74 | -7.57 | -8.65 | -6.72 | -6.63 | -6.63 |
| Book Value | 11.97 | 9.04 | 12.23 | 11.56 | 19.00 | 13.61 | 5.04 | 3.75 | 2.82 | -0.81 | -0.81 |
| Cash Flow/Share | -4.07 | -5.98 | -5.84 | -6.11 | -2.18 | -5.00 | -5.44 | -6.46 | -4.58 | -4.72 | -5.48 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 39.6M | 42.4M | 49.8M | 56.6M | 60.8M | 67.8M | 69.9M | 73.5M | 90.5M | 98.6M | 98.6M |
| Valuation | |||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -4.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 5.9 | 5.2 | 3.4 | 3.8 | 8.9 | 6.1 | 8.6 | 12.9 | 15.4 | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | 17.7 | 20.0 | 10.8 | 7.1 | 7.7 | 5.2 | 3.9 |
| FCF Yield | -6.1% | -12.9% | -14.1% | -15.1% | -1.7% | -7.3% | -16.3% | -14.6% | -10.7% | -14.0% | -17.8% |
| Market Cap | 2.8B | 2.0B | 2.1B | 2.5B | 10.3B | 5.6B | 3.0B | 3.5B | 3.9B | 3.4B | 2.7B |
| Avg. Price | 66.75 | 61.30 | 62.79 | 54.02 | 79.13 | 103.59 | 55.88 | 41.91 | 47.67 | 35.24 | 26.90 |
| Year-End Price | 71.22 | 46.97 | 41.87 | 43.41 | 169.89 | 83.05 | 43.52 | 48.27 | 43.42 | 34.19 | 26.90 |
Ultragenyx Pharmaceutical Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Ultragenyx Pharmaceutical Inc. (RARE) reported earnings per share (EPS) of $-5.83 in its most recent fiscal year.
Ultragenyx Pharmaceutical Inc. (RARE) has a return on equity (ROE) of -657.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 10 years of financial data for Ultragenyx Pharmaceutical Inc. (RARE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Ultragenyx Pharmaceutical Inc. (RARE) has a book value per share of $-0.81, based on its most recent annual SEC filing.